<110>	Griswold, Karl Edwin
	Scanlon, Thomas Carr

<120>	THERAPEUTIC CHARGE ENGINEERED VARIANTS OF LYSOZYME AND METHODS FOR USING THE SAME AS ANTIMICROBIAL THERAPIES

<130>	KGT-001PC

<140>   New Application
<141>	Concurrently Herewith

<150>	US 61/145,455
<151>	2009-01-16

<150>	US 61/222,780
<151>	2009-07-02


<160>	36

<210> 	1
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-3-7 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	1
KVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVDDPQGIRAWVAWRNHCQNRDVRQYVQGCGV


<210> 	2
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-1-1 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	2
KVFERCELARTLKDLGMDGYAGISLANWMCLAKWESGYNTDATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	3
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-1-2 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	3
KVFERCELARTLKNLGMDGYAGISLANWMCLAKWESGYNTDATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	4
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-3-1 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	4
KVFERCELARTLKALGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACDLSCSALLQDNIADAVACAKRVVDDPQGIRAWVAWRNACQNRDVAQYVQGCGV


<210> 	5
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-3-2 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	5
KVFERCELARTLKDLGMDGYAGISLANWMCLAKWESGYNTDATNYNAGDDSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNDCQNRDVRQYVQGCGV


<210> 	6
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-3-3 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	6
KVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVDDPQGIRAWVAWRNACQNRDVRQYVQGCGV


<210> 	7
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-3-4 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	7
KVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACDLSCSALLQDNIADAVACAKRVVADPQGIRAWVAWRNNCQNRDVRQYVQGCGV


<210> 	8
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-3-5 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	8
KVFERCELARTLKALGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACDLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	9
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-3-8 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	9
KVFERCELARTLKNLGMDGYAGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVDDPQGIRAWVAWRNRCQNRDVAQYVQGCGV


<210> 	10
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-3-9 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	10
KVFERCELARTLKALGMDGYNGISLANWMCLAKWESGYNTRATNYNAGDDSTDYGIFQINSRYWCNDGKTPGAVNACNLSCSALLQDNIADAVACAKRVVDDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	11
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-3-10 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	11
KVFERCELARTLKALGMDGYAGISLANWMCLAKWESGYNTRATNYNAGDASTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	12
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-3-11 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	12
KVFERCELARTLKALGMDGYAGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACALSCSALLQDNIADAVACAKRVVADPQGIRAWVAWRNRCQNRDVDQYVQGCGV


<210> 	13
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-3-12 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	13
KVFERCELARTLKNLGMDGYAGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACDLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNNCQNRDVRQYVQGCGV


<210> 	14
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant 2-5-1 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	14
KVFERCELARTLKALGMDGYNGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACALSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	15
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant D9 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	15
KVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTQATNYNAGDQSTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNQCQNRDVRQYVQGCGV


<210> 	16
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant E4 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	16
KVFERCELARTLKELGMDGYAGISLANWMCLAKWESGYNTRATNYNAGDQSTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	17
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant F10 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	17
KVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDASTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNQCQNRDVRQYVQGCGV


<210> 	18
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant G6 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	18
KVFERCELARTLKALGMDGYAGISLANWMCLAKWESGYNTQATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNQCQNRDVRQYVQGCGV


<210> 	19
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant D7 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	19
KVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVADPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	20
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant F8 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	20
KVFERCELARTLKELGMDGYAGISLANWMCLAKWESGYNTQATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	21
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant G4 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	21
KVFERCELARTLKALGMDGYAGISLANWMCLAKWESGYNTEATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	22
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant A3 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	22
KVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDASTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVADPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	23
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant B3 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	23
KVFERCELARTLKQLGMDGYQGISLANWMCLAKWESGYNTRATNYNAGDASTDYGIFQINSRYWCNDGKTPGAVNACALSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	24
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant B4 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	24
KVFERCELARTLKQLGMDGYAGISLANWMCLAKWESGYNTRATNYNAGDESTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVQDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	25
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant C3 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	25
KVFERCELARTLKALGMDGYQGISLANWMCLAKWESGYNTQATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACALSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	26
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant C6 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	26
KVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTQATNYNAGDQSTDYGIFQINSRYWCNDGKTPGAVNACALSCSALLQDNIADAVACAKRVVQDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	27
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant D6 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	27
KVFERCELARTLKELGMDGYAGISLANWMCLAKWESGYNTQATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	28
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant F9 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	28
KVFERCELARTLKQLGMDGYAGISLANWMCLAKWESGYNTQATNYNAGDQSTDYGIFQINSRYWCNDGKTPGAVNACELSCSALLQDNIADAVACAKRVVEDPQGIRAWVAWRNRCQNRDVRQYVQGCGV


<210> 	29
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant A111 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	29
KVFERCELARTLKALGMDGYAGISLANWMCLAKWESGYNTEATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNHCQNRDVRQYVQGCGV


<210> 	30
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant C13 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	30
KVFERCELARTLKELGMDGYQGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNHCQNRDVRQYVQGCGV


<210> 	31
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant G15 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	31
KVFERCELARTLKNLGMDGYAGISLANWMCLAKWESGYNTQATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNHCQNRDVRQYVQGCGV


<210> 	32
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant G18 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	32
KVFERCELARTLKALGMDGYAGISLANWMCLAKWESGYNTQATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNHCQNRDVRQYVQGCGV


<210> 	33
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant A26 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	33
KVFERCELARTLKALGMDGYQGISLANWMCLAKWESGYNTQATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNHCQNRDVRQYVQGCGV


<210> 	34
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant G211 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	34
KVFERCELARTLKALGMDGYAGISLANWMCLAKWESGYNTQATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACALSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNHCQNRDVRQYVQGCGV


<210> 	35
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant C25 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	35
KVFERCELARTLKELGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVADPQGIRAWVAWRNHCQNRDVRQYVQGCGV


<210> 	36
<211>	130
<212>	PRT
<213>	Artificial Sequence

<220>
<223>	Genetically engineered protein variant D25 of human lysozyme exhibiting reduced molecular charge and enhanced antimicrobial activity

<400>	36
KVFERCELARTLKALGMDGYAGISLANWMCLAKWESGYNTRATNYNAGDASTDYGIFQINSRYWCNDGKTPGAVNACQLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNHCQNRDVRQYVQGCGV

